Investors

Press Releases

Date Title View
Toggle Summary Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy Volunteers
M281 data shows safety and tolerability with no serious adverse events CAMBRIDGE, Mass. , Jan. 05, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today reported positive top-line
View HTML
Toggle Summary Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)
Targeting the initiation of a pivotal patient clinical trial in the first half of 2018 CAMBRIDGE, Mass. , HERTFORDSHIRE, United Kingdom and PITTSBURGH , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL) today announced the
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the 36th Annual J. P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Dec. 28, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Craig Wheeler , President and CEO, will present at the 36th Annual J. P.
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
-- Ended third quarter with a strong cash position of $423M -- CAMBRIDGE, Mass. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the third quarter ended September 30, 2017 and provided a corporate update.
View HTML
Toggle Summary Momenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)
CAMBRIDGE, Mass. and HERTFORDSHIRE, United Kingdom and PITTSBURGH , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL), today announced that M834, a proposed biosimilar of ORENCIA (abatacept), did not meet its primary pharmacokinetic
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of Third Quarter 2017 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , Oct. 18, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the third quarter ended September 30, 2017 before the U.S.
View HTML
Toggle Summary Momenta Pharmaceuticals Promotes Ganesh V. Kaundinya as Chief Operating Officer and Chief Scientific Officer
Industry pioneer to expand Chief Scientist role to include operations
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the 2017 Wells Fargo Healthcare Conference
CAMBRIDGE, Mass. , Aug. 30, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it plans to provide a corporate overview, including an update on its collaboration
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
  $10M milestone payment from Sandoz earned for the second anniversary of Glatopa ® 20 mg as the sole FDA -approved generic on the market for patients with relapsing forms of multiple sclerosis   Ended second quarter with a strong cash position of $457M  CAMBRIDGE, Mass., Aug.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Jury Verdict in Enoxaparin Sodium Injection Patent Litigation Against Amphastar
CAMBRIDGE, Mass. , July 21, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that the jury in the District Court for the District of Massachusetts in Boston has issued its verdict finding that the Company's U.S. Patent No.
View HTML